The Biologics News and Reports Portal

Show Cart

Immuno-Oncology

Results 1 - 13 of 13

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

120.00 €

Jul 2018 Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

1,440.00 €

2,400.00 €

(Discount: 40.00%)

Jul 2018 Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

800.00 €

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

500.00 €

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

500.00 €

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

600.00 €

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

3,080.00 €

4,400.00 €

(Discount: 30.00%)

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

2,150.00 €

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Immuno-Oncology

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Apr 2020 STING Agonists & Antagonists – Target Pipeline List 04/2020

Feb 2020 TIGIT-Targeted Immunotherapeutics – Target Pipeline List 02/2020

Sep 2019 Competitor Analysis: TGF-beta/Receptor Inhibitors

Jul 2019 CD137 Costimulatory Receptor Agonists – Target Pipeline List 07/2019

Nov 2018 MerTK Inhibitors – Target Pipeline List 11/2018

Jul 2018 Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators

Jul 2018 Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

Jun 2018 Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

Oct 2017 Report Package: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics

Jan 2017 The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing